STRAIN SPECIFICITY OF ANTI-CRYPTOSPORIDIUM IGG

抗隐孢子虫 IGG 的菌株特异性

• 批准号: 3489545
• 负责人: JOSEPH H. CRABB
• 金额: $ 5万
• 依托单位: IMMUCELL CORPORATION
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-04-01 至 1993-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489545
• 关键词: AIDS; Cryptosporidium; antigen antibody reaction; antiviral antibody; colostrums; cow; cryptosporidiosis; disease /disorder model; genetic strain; immunoglobulin G; immunological substance; immunosuppression; laboratory mouse; method development; neutralizing antibody; opportunistic infections; passive immunization; protozoal antigen

DESCRIPTION: (Adapted from the applicant's abstract) Cryptosporidium parvum is a significant human pathogen for which no chemotherapy has been shown to be efficacious. The number of cases of human cryptosporidiosis has increased dramatically in the last decade, particularly in the population of immunocompromised individuals. In the AIDS population, the mortality rate of Cryptosporidium infected individuals exceeds 60 percent. Hyperimmune anti-Cryptosporidium bovine colostrum, has shown a great deal of promise in limited human studies, providing therapeutic benefit to 7 of 8 cryptosporidiosis patients thus far treated. A possible impediment to the successful development of a Cryptosporidium bovine colostral immunoglobulin product is the potential for antigenic diversity among isolates or strains of this parasite, as there is a paucity of data addressing this issue. This proposal focuses on evaluating cross-reactivity and cross-neutralizing capacity against C. parvum isolates from calves and humans and from geographically diverse regions using anti-Cryptosporidium colostral immunoglobulin preparations with demonstrated protective properties. The long term objective is to discover strains that elicit broad cross-neutralizing antibodies for human therapeutic use.

描述：（改编自申请人的摘要）隐孢子虫 Parvum是一种重要的人类病原体，没有化学疗法 被证明是有效的。 人类隐孢子虫病的病例数 在过去的十年中，尤其是在 免疫功能低下的个体人群。 在艾滋病人群中 隐孢子虫感染个体的死亡率超过60％。 超免疫抗晶状体牛乳纤维表现出了很大的作用 在有限的人类研究中有希望的有望，为7个 迄今为止，已治疗8例隐孢子虫病患者。 可能的障碍 隐孢子虫的成功发展 免疫球蛋白产品是在抗原多样性之间的潜力 该寄生虫的分离株或菌株，因为数据很少 解决这个问题。 该建议重点是评估 针对C. parvum的交叉反应性和交叉中和能力 来自小牛和人类以及地理上不同地区的分离株 使用抗晶状体孢子孢子虫免疫球蛋白制剂 展示的保护特性。 长期目标是 发现引起人类的广泛跨中和抗体的菌株 治疗用途。